BioTuesdays

Tag - BTIG

Teknova
Markets

Analysts start Alpha Teknova at outperform, buy

Analysts for William Blair and BTIG initiated coverage of Alpha Teknova (NASDAQ:TKNO) with “outperform” and “buy” ratings, respectively, citing the company’s exposure to several large, rapidly growing markets.  “In...

July 20, 2021
Verastem
Markets

BTIG ups Verastem to buy from neutral; PT $8

BTIG upgraded Verastem (NASDAQ:VSTM) to “buy” from “neutral” with a new price target of $8, citing a breakthrough designation from the FDA for its KRAS-focused combination therapy of VS-6766 with defactinib for all...

May 24, 2021
Mereo-BioPharma
Markets

BTIG starts Mereo Biopharma at buy; PT $10

BTIG initiated coverage of Mereo Biopharma (NASDAQ:MREO) with a “buy” rating and price target of $10. The stock closed at $3.49 on May 4. “We believe Mereo shares are significantly undervalued with abundant proof-of...

May 5, 2021
DermTech-Logo
Markets

BTIG starts DermTech at buy; PT $53

BTIG initiated coverage of DermTech (NASDAQ:DMTK) with a “buy” rating and $53 price target. The stock closed at $42.05 on April 30. DermTech provides genomic diagnostic testing for various skin diseases and conditions...

May 3, 2021
Gain-Therapeutics-Logo
Markets

BTIG starts Gain Therapeutics at buy; PT 30

BTIG initiated coverage of Gain Therapeutics (NASDAQ:GANX) with a “buy” rating and $30 price target. The stock closed at $13.98 on April 9. Gain is a computational and medicinal chemistry-based biotechnology company...

April 12, 2021
iCAD-Logo
Markets

BTIG starts iCAD at buy; PT $25

BTIG initiated coverage of iCAD (NASDAQ:ICAD) with a “buy” rating and a price target of $25. The stock closed at $19.35 on March 22. iCAD is a medical technology company focused on cancer care, offering both cutting...

March 23, 2021
Seelos Therapeutics Logo
Markets

BTIG starts Seelos Therapeutics at buy; PT $14

BTIG initiated coverage of Seelos Therapeutics (NASDAQ:SEEL) with a “buy” rating and $14 price target. The stock closed at $3.04 on March 11. Seelos’ lead clinical candidate, SLS-002, is an intranasally delivered...

March 12, 2021